Holen Sie sich die Stockscreener-App
37.29
3.32%
-1.28
Vorhandelsmarkt:
38.32
1.03
+2.76%
Schlusskurs vom Vortag:
$38.57
Offen:
$38.47
24-Stunden-Volumen:
448.60K
Relative Volume:
1.03
Marktkapitalisierung:
$751.89M
Einnahmen:
$1.77M
Nettoeinkommen (Verlust:
$-123.74M
KGV:
-4.0665
EPS:
-9.17
Netto-Cashflow:
$-95.21M
1W Leistung:
-1.53%
1M Leistung:
-56.97%
6M Leistung:
-37.73%
1J Leistung:
-32.43%
1-Tages-Spanne:
$36.55
$39.34
1-Wochen-Bereich:
$34.91
$39.44
52-Wochen-Spanne:
$33.01
$91.83
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Firmenname
Praxis Precision Medicines Inc
Sektor
Branche
Telefon
617-300-8460
Adresse
99 HIGH STREET, 30TH FLOOR, BOSTON
Vergleichen Sie PRAX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
37.29 | 751.89M | 1.77M | -123.74M | -95.21M | -9.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-03 | Bestätigt | H.C. Wainwright | Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-08-05 | Eingeleitet | Oppenheimer | Outperform |
| 2024-06-24 | Eingeleitet | Needham | Buy |
| 2024-06-18 | Eingeleitet | Guggenheim | Buy |
| 2024-05-01 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-09-19 | Eingeleitet | Truist | Buy |
| 2022-06-06 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-12-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-08-26 | Eingeleitet | BofA Securities | Buy |
| 2021-04-26 | Eingeleitet | William Blair | Outperform |
| 2020-11-11 | Eingeleitet | Wedbush | Outperform |
| 2020-11-10 | Eingeleitet | Cowen | Outperform |
| 2020-11-10 | Eingeleitet | Evercore ISI | Outperform |
| 2020-11-10 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Praxis Precision Medicines Inc Aktie (PRAX) Neueste Nachrichten
HC Wainwright Has Negative Estimate for PRAX Q1 Earnings - Defense World
Praxis Precision Medicines Updates on Programs and Finances - TipRanks
New York State Common Retirement Fund Boosts Holdings in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
Rhumbline Advisers Cuts Stake in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
Praxis Precision Medicines (NASDAQ:PRAX) Hits New 1-Year Low Following Analyst Downgrade - Defense World
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Praxis Adds Six New Hires With $33.55 Stock OptionsWhat's Behind This Talent Acquisition? - StockTitan
Praxis Precision Medicines to Participate in Five Upcoming Investor Conferences - GlobeNewswire
Praxis Precision price target lowered to $85 from $150 at Needham - Yahoo Finance
CNS Therapy Developer PRAX Lines Up Five Major Investor ConferencesWhat's Their 2025 Strategy? - StockTitan
Praxis: Still A 'Hold' Despite Interim Analysis Setback Of Ulixacaltamide (NASDAQ:PRAX) - Seeking Alpha
Praxis Precision Medicines (NASDAQ:PRAX) Given New $105.00 Price Target at HC Wainwright - Defense World
Praxis Precision Medicines (NASDAQ:PRAX) Price Target Cut to $85.00 by Analysts at Needham & Company LLC - Defense World
Praxis Precision Medicines (NASDAQ:PRAX) Given New $73.00 Price Target at Robert W. Baird - Defense World
Praxis Precision Medicines (NASDAQ:PRAX) Price Target Lowered to $85.00 at Truist Financial - Defense World
Praxis: A High-Risk, High-Reward Epilepsy Play Post Ulixacaltamide (Rating Upgrade) - Seeking Alpha
Analysts Cut Price Targets For Praxis Precision After Trial Setback For Essential Tremor Candidate - Benzinga India
Praxis Precision (PRAX) Stock Price Target Cut By Half - AskTraders
Praxis Precision price target lowered to $85 from $175 at Truist - TipRanks
Praxis Precision Medicines Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Praxis Precision tanks on negative ulixacaltamide news - The Pharma Letter
Deutsche Bank Adjusts Praxis Precision Medicines Price Target to $65 From $111, Maintains Buy Rating - Marketscreener.com
Assessing Praxis Precision Medicine: Insights From 5 Financial Analysts - Benzinga
Praxis Precision Medicines: A Compelling Buy Amidst Promising Pipeline Developments - TipRanks
Praxis Precision Medicines (NASDAQ:PRAX) Shares Gap Down After Earnings Miss - Defense World
Praxis Precision Medicines (PRAX) Projected to Post Quarterly Earnings on Friday - MarketBeat
Praxis cites doubts over late-stage trial success: Wedbush downgrades (update) - MSN
Praxis Precision Medicines Provides Update on Essential3 and Corporate Update - GlobeNewswire
Praxis to advance late-stage program for lead asset despite doubts over success - MSN
Praxis stock price target cut to $61 at TD Cowen By Investing.com - Investing.com Australia
Items Tagged with 'relutrigine' - BioWorld Online
Items Tagged with 'vormatrigine' - BioWorld Online
Praxis Aims To Complete ET Trial Despite Likely Primary Endpoint Miss - Citeline News & Insights
Praxis stock price target cut to $61 at TD Cowen - Investing.com India
Wedbush Downgrades Praxis Precision Medicines to Underperform From Neutral, Cuts Price Target to $26 From $57; Shares Fall - Marketscreener.com
Market Whales and Their Recent Bets on PRAX Options - Benzinga
H.C. Wainwright sees opportunity for quick rebound from Praxis after setback - TipRanks
Truist cuts Praxis stock target to $85, maintains buy rating By Investing.com - Investing.com South Africa
Truist cuts Praxis stock target to $85, maintains buy rating - Investing.com
Praxis Precision Medicines: Navigating Challenges and Catalysts in Epilepsy Treatment - TipRanks
Buy Rating Maintained for Praxis Precision Medicines Despite Essential3 Setback, Focus on Promising Pipeline and Strong Financial Position - TipRanks
Truist Securities Adjusts Praxis Precision Medicines Price Target to $85 From $175, Maintains Buy Rating; Shares Plunge - Marketscreener.com
Recursion Pharmaceuticals, DoubleVerify Holdings, Praxis Precision Medicines - TradingView
Praxis Precision Medicines, Inc. (PRAX) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Praxis Precision Medicines Says it Gets Recommendation From IDMC to Stop Study 1 of Essential3 Program - Marketscreener.com
Praxis' tremor drug trial unlikely to meet main goal -February 28, 2025 at 08:36 am EST - Marketscreener.com
Independent committee says Praxis' tremor drug trial unlikely to meet main goal -February 28, 2025 at 08:12 am EST - Marketscreener.com
Praxis Precision Medicines, Inc. SEC 10-K Report - TradingView
Praxis Suffers Clinical Trial Setback: What's Next for Their $469M Pipeline? - StockTitan
Praxis Precision Medicines (NASDAQ:PRAX) Stock Price Down 8.5%Here's What Happened - MarketBeat
Praxis Precision Medicines, Inc. (PRAX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release - MSN
Finanzdaten der Praxis Precision Medicines Inc-Aktie (PRAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.39%
0.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):